[The tolerability and efficacy of combined antidepressant therapy: literature review].
There are many pharmacological strategies in order to manage depressed patients with treatment resistance. Combined antidepressants therapy is currently prescribed, mostly for depressions which resist to a single antidepressant, or to another therapeutic, such as electric-convulsive-therapy. Combined treatments are usually considered to have a more rapid action than monotherapy, although mainly is based on personal experience. It is generally admitted that the better efficacy of combined antidepressants therapy with different biochemical characteristics is explained by the synergic action of both norepinephrine and serotonin systems. The combination treatment of MAOI and tricyclic agents has been widely studied, sometimes on hundreds of patients. Numerous studies showed a good efficacy, and the toxicity of such an association was exaggerated, thus they are nevertheless rarely prescribed. As reversible MAOI-A are now available, combination treatment with tricyclic antidepressants is theoretically safer. The combination treatment of SSRI and tricyclic antidepressants is more frequently reported in the recent literature. Studies analysing such an association are however insufficient, and cannot lead to any clear conclusion. The combined treatment of mianserin and tricyclic antidepressants have also been quoted, with an efficacy that has been confirmed on randomized placebo-controlled studies. Resistant depressions are the main indication for combined antidepressants therapy. Anxious disorders have recently been considered as interesting new indications, such as panic disorder or obsessive compulsive disorder, with or without a comorbid mood disorder. In conclusion, controlled studies devoted to the analysis of combined antidepressants therapy are relatively few, and do not allow to draw any conclusion about their efficacy. Nevertheless, as this type of prescription is frequent, scientific evaluation of their specific efficacy is needed.
Taleb
M
M
Service de Psychiatrie, Hôpital René-Dubos, Pontoise.
Gorwood
P
P
Bouleau
J H
JH
Rouillon
F
F
D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*
D000929:Antidepressive Agents, Tricyclic; D008996:Monoamine Oxidase Inhibitors